Jefferies Financial Group Cuts Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target to $8.00

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price target cut by Jefferies Financial Group to $8.00 in a report published on Monday,Benzinga reports. They currently have a buy rating on the stock.

EYPT has been the subject of a number of other research reports. Chardan Capital reissued a “neutral” rating and issued a $5.00 target price (down from $65.00) on shares of Eyepoint Pharmaceuticals in a report on Monday. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Eyepoint Pharmaceuticals in a report on Monday. Royal Bank Of Canada lowered their price objective on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Cantor Fitzgerald downgraded shares of Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday. Finally, Guggenheim restated a “buy” rating and issued a $68.00 target price on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $28.11.

Eyepoint Pharmaceuticals Stock Up 15.2%

Shares of EYPT stock opened at $6.30 on Monday. Eyepoint Pharmaceuticals has a twelve month low of $3.95 and a twelve month high of $19.11. The company has a market cap of $543.12 million, a P/E ratio of -1.68 and a beta of 1.76. The business has a fifty day simple moving average of $12.85 and a 200 day simple moving average of $13.49.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The business had revenue of $0.51 million during the quarter, compared to analyst estimates of $0.45 million. As a group, equities research analysts anticipate that Eyepoint Pharmaceuticals will post -3.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Several large investors have recently bought and sold shares of the company. KBC Group NV acquired a new stake in shares of Eyepoint Pharmaceuticals during the first quarter valued at about $29,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Eyepoint Pharmaceuticals by 51.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock worth $74,000 after purchasing an additional 1,358 shares during the last quarter. California State Teachers Retirement System increased its stake in shares of Eyepoint Pharmaceuticals by 20.6% in the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock valued at $85,000 after buying an additional 794 shares during the period. Russell Investments Group Ltd. acquired a new position in shares of Eyepoint Pharmaceuticals in the third quarter valued at approximately $76,000. Finally, Persistent Asset Partners Ltd acquired a new position in shares of Eyepoint Pharmaceuticals in the fourth quarter valued at approximately $98,000. 99.41% of the stock is currently owned by institutional investors.

Trending Headlines about Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: EyePoint said the primary-endpoint miss was largely attributable to nine patients—approximately 4% of the study population—who experienced vision loss unrelated to wet AMD. The company also pointed to favorable secondary endpoints, reduced treatment burden and durable disease control, which could preserve the broader DURAVYU investment case. EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown
• Positive Sentiment: Upcoming LUCIA Phase 3 data, expected in the fourth quarter of 2026, is now a major catalyst. A positive result could help revive confidence in DURAVYU and partially offset the LUGANO failure.
• Positive Sentiment: Citigroup maintained a buy rating while reducing its price target to $17, implying substantial potential upside if the remaining clinical program succeeds.
• Neutral Sentiment: Unusually active options trading included the purchase of about 3,011 call contracts, above average volume. This may reflect speculative positioning around the stock’s volatility and upcoming clinical catalysts rather than a fundamental improvement.
• Negative Sentiment: The LUGANO trial’s failure to achieve its primary endpoint sharply weakened the clinical and regulatory case for DURAVYU in wet AMD. Analysts have questioned whether the secondary results can compensate for the failed head-to-head outcome. EYPT Stock Plunges After Duravyu Misses Phase III Eye Disease Goal
• Negative Sentiment: Royal Bank of Canada downgraded EyePoint to hold and Chardan Capital cut its rating to neutral; both cited $5 price targets. Cantor Fitzgerald also moved to neutral, while Jefferies lowered its expectations. Chardan, JPMorgan and HC Wainwright otherwise maintained neutral-type views.
• Negative Sentiment: The stock reached a new 12-month low as investors reassessed EyePoint’s valuation, execution risk and dependence on future clinical data. EyePoint Hits New 12-Month Low After Analyst Downgrade

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.